Explore the world of Biopharmaceuticals

Teva is investing in biopharmaceuticals as part of our long term strategy for the future, and to help patients around the world. We are focusing on treatments for the central nervous system, respiratory conditions, and in the field of oncology.

Biopharmaceuticals are complex medicines made from living cells or organisms. They advance more treatment options for patients, some of whom suffer from untreated or undertreated conditions. They have the potential to deliver precise and personalized treatment.

Biosimilars

Together with creating original biologic medicines, Teva is investing in biosimilars. These are highly similar versions of reference biological treatments. This focus on biosimilars is a natural progression for Teva following our role in the development of the generic medicine industry over the past 100 years. They combine our strength in generics with our knowledge of complex medicine.

Biosimilar medicines have generated €56 billion in cumulative savings for European healthcare systems, including €16 billion over 2023 – 2024 alone. 01

The HSE and Biopharmaceuticals

Biosimilar medicines are integral to the Health Service Executive (HSE). Their use provides significant savings to the HSE and widens access to more medicines for patients earlier.

Biological medicines in particular have revolutionised patient treatment by offering new and effective treatment options for acute and chronic conditions including neutropenia, cancer, a wide range of inflammatory and autoimmune diseases, and enzyme or hormone deficiencies.

The story of biopharmaceuticals

Teva's Steffen Nock takes us on a brief journey through the story of biopharmaceuticals, he charts where biopharmaceuticals came from and where they might be going in the future.

Products and pipeline

Teva has multiple biopharmaceuticals currently on the market. In addition, we are advancing many more original biologic and biosimilar programs across all stages of development, from early discovery through clinical and regulatory phases. 

Many of these treatments will be produced in our new $500 million state-of-the-art biopharmaceutical plant in Ulm, Germany.

The benefit that biopharmaceuticals will bring to patients is what inspires us as we invest in this exciting future. 

Biopharmaceutical innovation will not take place overnight but we are committed to seeing the impact and results of our investment over the next decade.